NOVN.SW

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease.

Novartis AG (NOVN.SW) is a healthcare company listed on SIX Swiss Exchange, traded in CHF. Over the past year it moved between CHF 99.15 and CHF 135.06, and it pays a dividend once a year.

• Healthcare
• Drug Manufacturers - General
• Basel, Switzerland
• 75.3K employees
• Led by Vasant Narasimhan M.D.